Clinical Research Directory
Browse clinical research sites, groups, and studies.
CAR T-cell Therapy in Patients With Renal Dysfunction
Sponsor: Northside Hospital, Inc.
Summary
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
Official title: Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2024-11-18
Completion Date
2027-08-31
Last Updated
2025-10-30
Healthy Volunteers
No
Interventions
Fludarabine
Received IV on Days -5 to -3 before CAR T cell therapy
Cyclophosphamide
Received IV on Days -5 to -3 before CAR T cell therapy
Locations (1)
Caitlin Guzowski
Atlanta, Georgia, United States